AI Governance in Pharmacovigilance: Building Defensible, Compliant AI Workflows for Regulatory Inspections in 2026 and Beyond

 Pharmacovigilance teams aren’t being asked whether they use AI anymore — they’re being asked to prove they can control it. That shift is what defines 2026.



Regulators have moved beyond curiosity about machine learning in drug safety. They expect pharmaceutical organizations to demonstrate how AI systems are governed, validated, monitored, and audited across the safety lifecycle. The joint release of guiding principles by the FDA and EMA in early 2026 made one thing explicit: AI governance in pharmacovigilance must be explainable, traceable, and inspection-ready — no different from any other GxP-regulated system.

For safety teams already using AI for safety signal detection and triage, or adverse event case processing automation with AI, the focus has changed. It’s no longer about efficiency gains alone; now, the aim is to ensure every model decision, automation rule, and LLM-generated narrative can withstand regulatory scrutiny.

Consequently, across safety forums, industry working groups, and internal governance boards, one operational question keeps surfacing:

How do you document, validate, and defend AI-driven decisions in pharmacovigilance workflows during an FDA or EMA inspection?

Addressing this question requires that organizations design compliant AI workflows intentionally, instead of retrofitting governance after deployment.

In this blog, we deep dive into the different aspects of AI governance in pharmacovigilance

READ MORE

Comments

Post a Comment

Popular posts from this blog

From First Contact to Case Record: AI-Powered Pharmacovigilance Intake with AWS Connect

Image
  Drug safety hotlines have operated the same way for decades. An agent picks up a call, listens, and types what they hear into a case management system. When the call ends, they review their notes, fill in gaps, and route the case for medical review. It is a process built on human attention and manual transcription — and it has not fundamentally changed since PV call centres first came into existence. The volume of adverse event reports, however, has increased. Global drug portfolios now generate case volumes growing to 20% annually. A serious adverse event reported at 11 PM in one time zone triggers regulatory obligations that don’t wait for business hours in another. And a missed or inaccurately transcribed seriousness criterion can have consequences that reach from the case record all the way to a regulatory inspection. This is the operational context in which AWS Connect telephony for pharmacovigilance is gaining serious attention from drug safety teams. Not as a replacement f...
Read more

From Literature Noise to Actionable Insights: Automating End-to-End Surveillance

Image
  Every week, a pharmacovigilance team opens their literature monitoring queue to find hundreds of articles pulled from PubMed, EMBASE, and regional databases. The majority of these articles are often duplicates, off-label mentions, or pharmacokinetic studies that lack any meaningful adverse event content, adding unnecessary noise to the process.  This is precisely the problem that  AI literature management  is designed to solve — not by adding another layer of retrieval, but by bringing intelligence into every stage of the workflow. The EMA’s own 2024 Annual Report on EudraVigilance puts this problem in clear numbers. In 2024, the agency reviewed 1,254 potential safety signals. Of those, 76% were not validated and closed. Only 3.1%, were ultimately prioritised and assessed by PRAC.  That ratio reflects a broader industry challenge: when literature monitoring generates excessive noise upstream, safety teams spend more time triaging irrelevant content than evalua...
Read more

From Case Intake to Signal Detection: How New-Age Technologies are Reshaping Pharmacovigilance Operations – How Clinevotech is Leading Innovation

Image
  The pharmaceutical landscape is currently witnessing an unprecedented explosion in data volume. From clinical trials and electronic health records to social media and scientific literature, the sources of safety data are multiplying exponentially. For   Pharmacovigilance (PV)   teams, this presents a critical dual challenge: managing vast quantities of data while ensuring stringent regulatory compliance with global bodies such as the FDA, EMA, and MHRA. The scale of this challenge is staggering. Consider that a single adverse event can be reported through multiple channels—spontaneous reports, literature mentions, social media discussions, and clinical trial databases. Each source requires intake, assessment, coding, and signal evaluation. Traditional manual processes, which were designed for a fraction of today’s data volumes, are buckling under the pressure. Case backlogs grow, signal detection delays increase, and compliance risks mount. This is where modern technolo...
Read more